Composition for filling bone defects

Claim 2

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising demineralized osteoinductive and osteoconductive bone particles in an aqueous carrier solution, said bone particles are alloaraft bone ranging from about 100 microns to about 850 microns in size at a concentration ranging from 20% to 35% by weight of the composition, the carrier comprising a hydrogel component of sodium hyaluronate or its derivatives in a phosphate buffered aqueous solution, said hydrogel ranging from about 1.0% to about 5.0% by weight of the aqueous carrier solution and cellular material taken from a group consisting of living cells, cell elements such as red blood cells, white blood cells, platelets, blood plasma, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells present at a concentration of 10 5 to 10 8 per cc of the carrier, said hydrogel component having a high molecular weight ranging from about six hundred sixty thousand to three million Daltons with a stable viscosity at a temperature ranging from about 22° C. to about 37° C. and said composition having a pH ranging from about 6.8 to about 7.4

Claim 3

A sterile formable bone composition as claimed in claim 1 including growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin celiular attractants and attachment agents.

Claim 4

A sterile formable bone composition as claimed in claim 1 including growth factor additive added to said composition comprising one or more of a group consisting of fibroblast growth factor (FGF) (numbers 1–23) in the amount of 2–4 milligrams in 10 cc of carrier solution.

Claim 5

A sterile formable bone composition as claimed in claim 1 wherein said composition includes an additive collagen and insoluble collagen derivatives.

Claim 6

A sterile formable bone composition as claimed in claim 1 wherein said composition includes the addition of calcium hydroxyapatite at a concentration of 20–35% measured as calcium.

Claim 7

A sterile formable bone composition as claimed in claim 1 wherein said composition includes bone chips taken from a group consisting of partially demineralized chips and non demineralized chips having a particle size ranging from 0.1 mm to 1.0 cm which are added to said viscous carrier at a concentration of about 5% to about 25%.

Claim 8

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising a demineralized or vartiallv demineralized osteoinductive and osteoconductive bone particles in an aqueous carrier solution, said bone particles ranging from about 100 microns to about 850 microns in size at a concentration ranging from about 20% to about 35% by weight of the composition the carrier comprising a hydrogel component of sodium hyaluronate or its derivatives in a phosphate buffered aqueous solution, said hydrogel ranging from about 1.0% to about 5.0% by weight of the aqueous carrier solution and said hydrogel component having a high molecular weight ranging from about six hundred sixty thousand to three million Daltons with a stable viscosity at a temperature ranging from about 22° C. to about 37° C., said composition having a pH ranging from about 6.8 to about 7.4 and a growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEOF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 9

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising a demineralized or vartiallv demineralized osteoinductive and osteoconductive bone particles in an aqueous carrier solution, said bone particles ranging from about 100 microns to about 850 microns in size at a concentration ranging from about 20% to about 35% by weight of the composition the carrier comprising a hydrogel component of sodium hyaluronate or its derivatives in a phosphate buffered aqueous solution, said hydrogel ranging from about 1.0% to about 5.0% by weight of the aqueous carrier solution and said hydrogel component having a high molecular weight ranging from about six hundred sixty thousand to three million Daltons with a stable viscosity at a temperature ranging from about 22° C. to about 37° C., said composition having a pH ranging from about 6.8 to about 7.4 and a growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEOF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 10

A sterile formable bone composition as claimed in claim 7 including a cellular material taken from a group consisting of living cells and cell elements such as chondrocytes, red blood cells, white blood cells, platelets, blood plasma, bone marrow cells, mesenchymal stem cells, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells. These cells or cell elements or combinations of the same are present at a concentration of 10 5 to 10 8 per cc of the carrier.

Claim 11

A sterile formable bone composition as claimed in claim 7 wherein said composition includes an additive collagen and insoluble collagen derivatives.

Claim 12

A sterile formable bone composition as claimed in claim 7 wherein said composition includes the addition of calcium hydroxyapatite at a concentration of 20–35% measured by weight of the compostion.

Claim 13

A sterile formable bone composition as claimed in claim 7 wherein said bone particles are taken from a group consisting of allograft bone, cortical allograft bone, corticalcancellous bone, cancellous bone, autologous bone and xenograft bone.

Claim 14

A sterile formable bone composition as claimed in claim 7 wherein said composition includes bone chips taken from a group consisting of partially demineralized chips and fully mineralized chips having a particle size ranging from 0.1 mm to 1.0 cm which are added to said viscous carrier at a concentration of about 5% to about 25%.

Claim 15

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising a demineralized osteoinductive and osteoconductive bone particles in an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from about 20% to about 50% (w/w), the carrier comprising a hydrogel taken from a group consisting of Dextran, carboxymethylcellulose (CMC) and hydroxypropylmethylcellulose (HPMC) in a phosphate buffered aqueous solution, said hydrogel ranging from about 15% to about 30% by weight of the aqueous carrier solution and said hydrogel component having a molecular weight ranging from twenty thousand to forty thousand Daltons with a stable viscosity at a temperature ranging from about 22° C. to about 37° C. and said composition having a pH ranging from about 6.8 to about 7.4 and a growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 16

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising a demineralized osteoinductive and osteoconductive bone particles in an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from about 20% to about 50% (w/w), the carrier comprising a hydrogel taken from a group consisting of Dextran, carboxymethylcellulose (CMC) and hydroxypropylmethylcellulose (HPMC) in a phosphate buffered aqueous solution, said hydrogel ranging from about 15% to about 30% by weight of the aqueous carrier solution and said hydrogel component having a molecular weight ranging from twenty thousand to forty thousand Daltons with a stable viscosity at a temperature ranging from about 22° C. to about 37° C. and said composition having a pH ranging from about 6.8 to about 7.4 and a growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 17

A sterile formable bone composition as claimed in claim 13 including a cellular material additive taken from a group consisting of living cells and cell elements such as chondrocytes, red blood cells, white blood cells, platelets, blood plasma, bone marrow cells, mesenchymal stem cells, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells, said cells or cell elements or combinations of the same being present at a concentration of 10 5 to 10 8 per cc of the carrier.

Claim 18

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising demineralized osteoinductive and osteoconductive bone particles an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from about 20% to about 50% (w/w), the carrier comprising a hydrogel taken from a group consisting of Dextran, carboxymethylcellulose (CMC) and hydroxypropyhnethylcellulose (HPMC) in a phosphate buffered aqueous solution, said hydrogel ranging from about 15% to about 30% by weight of the aqueous carrier solution and cellular material taken from a group consisting of living cells, cell elements such as red blood cells, white blood cells, platelets, blood plasma, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells present at a concentration of 10 5 to 10 8 per cc of the carrier, said hydrogel component having a molecular weight ranging twenty thousand to forty thousand Daltons with a stable viscosity and said composition having a pH ranging from about 6.8 to about 7.4

Claim 19

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising demineralized osteoinductive and osteoconductive bone particles an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from about 20% to about 50% (w/w), the carrier comprising a hydrogel taken from a group consisting of Dextran, carboxymethylcellulose (CMC) and hydroxypropyhnethylcellulose (HPMC) in a phosphate buffered aqueous solution, said hydrogel ranging from about 15% to about 30% by weight of the aqueous carrier solution and cellular material taken from a group consisting of living cells, cell elements such as red blood cells, white blood cells, platelets, blood plasma, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells present at a concentration of 10 5 to 10 8 per cc of the carrier, said hydrogel component having a molecular weight ranging twenty thousand to forty thousand Daltons with a stable viscosity and said composition having a pH ranging from about 6.8 to about 7.4

Claim 20

A sterile formable bone composition as claimed in claim 15 including growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 21

A sterile formable bone composition as claimed in claim 15 including growth factor additive added to said composition comprising one or more of a group consisting of fibroblast growth factor (FGF) (numbers 1–23) in the amount of 2–4 milligrams in 10 cc of carrier solution.

Claim 22

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising a demineralized osteo inductive and osteoconductive bone particles in an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from 5–50% (w/w), the carrier comprising a hydrogel taken from a group consisting of chitosan and sodium alginate in a phosphate buffered aqueous solution, said hydrogel ranging from about 5.0% to about 20.0% by weight of the aqueous carrier solution and said hydrogel component having a molecular weight ranging from ten thousand to three hundred thousand Daltons with a stable viscosity at a temperature ranging from about 22° C. to about 37° C. and said composition having a pH ranging from about 6.8 to about 7.4 and a growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 23

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising a demineralized osteo inductive and osteoconductive bone particles in an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from 5–50% (w/w), the carrier comprising a hydrogel taken from a group consisting of chitosan and sodium alginate in a phosphate buffered aqueous solution, said hydrogel ranging from about 5.0% to about 20.0% by weight of the aqueous carrier solution and said hydrogel component having a molecular weight ranging from ten thousand to three hundred thousand Daltons with a stable viscosity at a temperature ranging from about 22° C. to about 37° C. and said composition having a pH ranging from about 6.8 to about 7.4 and a growth factor additive added to said composition, said growth factor comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 24

A sterile formable bone composition as claimed in claim 18 including a cellular material additive taken from a group consisting of living cells and cell elements such as chondrocytes, red blood cells, white blood cells, platelets, blood plasma, bone marrow cells, mesenchymal stem cells, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells. These cells or cell elements or combinations of the same are present at a concentration of 10 5 to 10 8 per cc of the carrier.

Claim 25

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising demineralized osteoinductive and osteoconductive bone particles in an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from 5–50% (w/w), the carrier comprising a hydrogel taken from a group consisting of chitosan and sodium alginate in a phosphate buffered aqueous solution, said hydrogel ranging from about 5.0% to about 20.0% by weight of the aqueous carrier solution and cellular material taken from a group consisting of living cells, cell elements such as red blood cells, white blood cells, platelets, blood plasma, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells present at a concentration of 10 5 to 10 8 per cc of the carrier, said hydrogel component having a molecular weight ranging from ten thousand to three hundred thousand Daltons with a stable viscosity and said composition having a pH ranging from about 6.8 to about 7.4

Claim 26

A sterile formable bone composition for application to a bone defect site to promote new bone growth at the site comprising demineralized osteoinductive and osteoconductive bone particles in an aqueous carrier solution, the bone particles being added to a viscous carrier at a concentration ranging from 5–50% (w/w), the carrier comprising a hydrogel taken from a group consisting of chitosan and sodium alginate in a phosphate buffered aqueous solution, said hydrogel ranging from about 5.0% to about 20.0% by weight of the aqueous carrier solution and cellular material taken from a group consisting of living cells, cell elements such as red blood cells, white blood cells, platelets, blood plasma, pluripotential cells, osteoblasts, osteoclasts, and fibroblasts, epithelial cells, and endothelial cells present at a concentration of 10 5 to 10 8 per cc of the carrier, said hydrogel component having a molecular weight ranging from ten thousand to three hundred thousand Daltons with a stable viscosity and said composition having a pH ranging from about 6.8 to about 7.4

Claim 27

A sterile formable bone composition as claimed in claim 20 including growth factor additive added to said composition, said growth injector comprising one or more of a group consisting of transforming growth factor (TGF-beta), insulin growth factor (IGF-1); platlet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) (numbers 1–23), osteopontin, growth hormones such as somatotropin cellular attractants and attachment agents.

Claim 28

A sterile formable bone composition as claimed in claim 20 including growth factor additive added to said composition comprising one or more of a group consisting of fibroblast growth factor (FGF) (numbers 1–23) in the amount of 2–4 milligrams in 10 cc of carrier solution.